[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356863-105":59,"doc-detail-356863-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-effectiveness-of-capecitabine-and-temozolomide-across-endocrine-and-neuroendocrine-neoplasm-subtypes-enens-a-population-based-cohort-study-from-alberta-canada-20112021","Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011–2021)","","Capecitabine plus temozolomide (CAPTEM) is established for progression-free survival in pancreatic endocrine and neuroendocrine neoplasms, yet real-world benefit across other endocrine and neuroendocrine subtypes is unclear. A retrospective population-based cohort study included 159 adults with ENENs treated with CAPTEM in Alberta, Canada (2011–2021). Patients were stratified by primary site, treatment line, and cycle number. CAPTEM yielded similar PFS and OS for gastrointestinal versus pancreatic neuroendocrine neoplasms, but shorter PFS and OS for pulmonary and other ENEN subtypes. First-line use and ≥6 cycles strongly improved PFS and overall survival, supporting broader but more selective CAPTEM deployment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-effectiveness-of-capecitabine-and-temozolomide-across-endocrine-and-neuroendocrine-neoplasm-subtypes-enens-a-population-based-cohort-study-from-alberta-canada-20112021/356863/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-effectiveness-of-capecitabine-and-temozolomide-across-endocrine-and-neuroendocrine-neoplasm-subtypes-enens-a-population-based-cohort-study-from-alberta-canada-20112021/356863.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient group and treatment setting were analyzed in the study?","Question",{"text":112,"@type":113},"The study retrospectively evaluated 159 adults with endocrine and neuroendocrine neoplasm (ENEN) subtypes treated with CAPTEM in Alberta, Canada from 2011 to 2021.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did CAPTEM effectiveness differ between gastrointestinal and pancreatic subtypes versus pulmonary and other subtypes?",{"text":117,"@type":113},"CAPTEM showed comparable real-world effectiveness in gastrointestinal neuroendocrine neoplasms and pancreatic neuroendocrine neoplasms, while pulmonary neuroendocrine neoplasms and other ENEN subtypes had significantly shorter progression-free and overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were associated with improved progression-free and overall survival?",{"text":121,"@type":113},"Using CAPTEM in the first-line setting and receiving at least six treatment cycles were strongly associated with improved progression-free survival and overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356863,1790195006,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nReal-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011–2021)  \nAlda Aleksi 1,2,*, Kaiden D. Jobin 1, Malek B. Hannouf 2, Patrik Husi 3, Heather Halperin 4, Chris White-Gloria 5, Tasnima Abedin 6 and Dean Ruether 2  \nReceived: 1 April 2026  \nRevised: 10 May 2026  \nAccepted: 12 May 2026  \nPublished: 14 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada  \n2 Department of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Centre, Calgary, AB T2N 5G2, Canada  \n3 Department of Cellular, Molecular and Microbial Biology, University of Calgary, Calgary, AB T2N 4N1, Canada  \n4 Department of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada  \n5 Department of Biochemistry, University of Calgary, Calgary, AB T2N 4N1, Canada  \n6 Department of Statistics, University of Calgary, Calgary, AB T2N 4N1, Canada  \n* Correspondence: alda.aleksi@cancercarealberta.ca; Tel.: +1-403-521-3688; Fax: +1-238-1651  \nSimple Summary  \nThe oral chemotherapy combination of capecitabine and temozolomide (CAPTEM) is widely used for metastatic pancreatic neuroendocrine neoplasms (PNENs), but evidence supporting its use in other endocrine and neuroendocrine neoplasms (ENEN) subtypes remains limited. We conducted a population-based real-world study evaluating survival outcomes among patients with ENENs treated with CAPTEM in Alberta, Canada. Over a 10-year period, CAPTEM demonstrated comparable effectiveness in gastrointestinal neuroendocrine neoplasms relative to PNENs, but inferior outcomes in pulmonary neuroendocrine neoplasms and other non-gastroenteropancreatic endocrine & neuroendocrine neoplasms, ENENs. Importantly, administration of CAPTEM in the first-line setting and delivery of at least six treatment cycles were strongly associated with improved progression-free and overall survival. These findings support broader but more selective use of CAPTEM across ENEN subtypes and highlight treatment timing and duration as clinically relevant prognostic factors in routine oncology practice.  \nAbstract  \nCapecitabine plus temozolomide (CAPTEM) improves progression-free survival (PFS) in pancreatic endocrine and neuroendocrine neoplasms (PNENs), yet its real-world effectiveness across other endocrine and neuroendocrine neoplasm (ENEN) subtypes remains uncertain. We conducted a retrospective population-based cohort study including 159 adults with ENENs treated with CAPTEM in Alberta, Canada (2011–2021) . Patients were stratified by primary tumor site, treatment line, and number of CAPTEM cycles received. Kaplan–Meier methods and Cox proportional hazards models adjusted for age and sex were used to evaluate PFS and overall survival (OS) . Compared with pancreatic neuroendocrine neoplasms PNENs, gastrointestinal neuroendocrine neoplasms (GINENs) demonstrated similar PFSand OS. In contrast, pulmonary neuroendocrine neoplasms (PuNENs) and other ENENs (OENENs) were associated with significantly shorter PFS and OS. Use of CAPTEM in the first-line setting was associated with improved PFS (HR 0.56, 95% CI 0.40–0.78, p \u003C 0.001) and OS (HR 0.42, 95% CI 0.29–0.62, p \u003C 0.001) . Receipt of ≥6 treatment cycles was also  \nstrongly associated with superior PFS (HR 0.22, 95% CI 0.16–0.32, p \u003C 0.001) and OS (HR 0.22, 95% CI 0.14–0.34, p \u003C 0.001) . CAPTEM shows comparable real-world effectiveness in GINENs and PNENs but appears less effective in PuNENs and other OENEN subtypes. Early initiation and adequate treatment duration are key factors associated with improved survival outcomes.  \nKeywords: neuroendocrine neoplasms; endocrine neoplasms; CAPTEM; real-world; retrospective cohort; overall surv","cbCaipdLCI31hfct","https://ap.wps.com/l/cbCaipdLCI31hfct","pdf",732389,18,"English","# Background\n## Study aims and real-world context\n# Abstract\n## Patient cohort and outcomes\n## Comparisons across ENEN subtypes\n## Prognostic impact of treatment line and cycle number","[{\"question\":\"What patient group and treatment setting were analyzed in the study?\",\"answer\":\"The study retrospectively evaluated 159 adults with endocrine and neuroendocrine neoplasm (ENEN) subtypes treated with CAPTEM in Alberta, Canada from 2011 to 2021.\"},{\"question\":\"How did CAPTEM effectiveness differ between gastrointestinal and pancreatic subtypes versus pulmonary and other subtypes?\",\"answer\":\"CAPTEM showed comparable real-world effectiveness in gastrointestinal neuroendocrine neoplasms and pancreatic neuroendocrine neoplasms, while pulmonary neuroendocrine neoplasms and other ENEN subtypes had significantly shorter progression-free and overall survival.\"},{\"question\":\"Which factors were associated with improved progression-free and overall survival?\",\"answer\":\"Using CAPTEM in the first-line setting and receiving at least six treatment cycles were strongly associated with improved progression-free survival and overall survival.\"}]","Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011–2021) | PDF",1790127785,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0906ee11009e6195f6aa9248449d505.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e11bb4171fea9d9b753e919ec6b652fa.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ca8616dc5cdc50b969c7c28014180a6.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26f25aa6f0c07cfb94fe00d6ef16bb49.webp",980,1385]